Kyverna Q2: $199M Cash, RMAT for MS, Rolling BLA for SPS — Runway Into 2028
KYTX has more than doubled off its 52-week low of $2.8.
Summary
Kyverna reported Q2 2026 results with $199.4M in cash, extending runway into 2028. The FDA granted RMAT designation for miv-cel in multiple sclerosis, and the company initiated a rolling BLA submission for stiff person syndrome.
Key Events · Earnings and Guidance · KYTX
-
Cash Runway Extended Into 2028
Cash, equivalents, and marketable securities totaled $199.4 million as of June 30, 2026. Combined with the amended Oxford loan facility and ATM proceeds, management expects this to fund operations into 2028, removing near-term dilution risk.
-
RMAT Designation for miv-cel in MS
The FDA granted Regenerative Medicine Advanced Therapy designation for miv-cel in non-active secondary progressive multiple sclerosis, providing eligibility for priority review, rolling review, and accelerated approval pathways.
-
Rolling BLA Submission Initiated for SPS
Kyverna began a rolling Biologics License Application submission for miv-cel in stiff person syndrome, seeking priority review. The CMC module was submitted in July 2026, with completion expected in Q4 2026.
-
Positive Phase 2 Data in SPS and gMG
At the AAN 2026 meeting, miv-cel demonstrated statistically significant, durable clinical benefit in the registrational KYSA-8 trial in SPS and sustained responses out to one year in the KYSA-6 trial in gMG.
Analysis · KYTX · Life Sciences
Kyverna's Q2 report delivers a trifecta of positive catalysts: a cash runway extending into 2028, a new RMAT designation for miv-cel in multiple sclerosis, and the initiation of a rolling BLA submission for stiff person syndrome. The $199.4 million cash position, combined with the amended loan facility, removes near-term financing risk. The RMAT designation opens accelerated approval pathways in a third indication, while the rolling BLA puts the company on track for a potential first approval. These developments materially de-risk the investment thesis for a late-stage biotech with no approved products.
At the time of this filing, KYTX was trading at $8.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487.6M. The 52-week trading range was $2.80 to $13.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.